1. ¹Section Recherche, Institut Curie, U612 INSERM, 26 rue d'Ulm, Paris 75248, France
2. ²Cancérologie Médicale, Hôpital Européen Georges Pompidou, 20 rue Leblanc, Paris 75015, France
3. ³Anatomie Pathologique, Hôpital Cochin, Paris 75005, France
4. ⁴Section Médicale, Institut Curie, Paris 75248, France

Correspondence: Dr M-F Poupon, E-mail: marie-france.poupon@curie.fr

Revised 4 October 2006; Accepted 14 November 2006; Published online 9 January 2007.

Abstract

Antitumour activity of docetaxel (Taxotere^®) in hormone-dependent (HD) and hormone-independent (HID) prostate cancer PAC120 xenograft model was previously reported, and its level was associated with HER2 protein expression. In the present study, we evaluate the antitumour effects of docetaxel combined with trastuzumab (Herceptin^®), an anti-HER2 antibody. Although trastuzumab alone had no effect on tumour growth, it potentiated the antitumour activity of docetaxel in HD tumours and more strongly in HID variants. Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24 h after docetaxel treatment, while HER2 protein and p-AKT decreased. This was followed by an increase of HER2 protein 3 days (two-fold) after docetaxel treatment and by a strong HER2 release in the serum of treated mice; expression of phospho-ERK, p27, BCL2 and HSP70 concomitantly increased. Similar molecular alterations were induced by docetaxel plus trastuzumab combination, except for that there was a transient and complete disappearance of AR and HSP90 proteins 24 h after treatment. We show that in addition to its known effects on tubulin and mitotic spindles, docetaxel induces complex signalisation pathway mechanisms in surviving cells, including HER2, which can be pharmacologically targeted. This study suggests that the docetaxel/trastuzumab combination may prove an effective therapeutic approach for HER2-expressing hormone-refractory prostate cancer.